EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles

Guijin Tang, Dawei Wang, Xiangqian Zhao, Zhihua Feng, Qi Chen iD, Yangkun Shen

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24043681 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Guijin Tang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, Qishan Campus, Fujian Normal University, College Town, Fuz…. Hauptthemen laut MEDLINE: Oncolytic Viruses, Herpesvirus 1, Human, Oncolytic Virotherapy, Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of Fujian Province, China, Department of Science and Technology of Fujian Province, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic viruses (OVs) have emerged as effective gene therapy and immunotherapy drugs. As an important gene delivery platform, the integration of exogenous genes into OVs has become a novel path for the advancement of OV therapy, while the herpes simplex virus type 1 (HSV-1) is the most commonly used. However, the current mode of administration of HSV-1 oncolytic virus is mainly based on the tumor in situ injection, which limits the application of such OV drugs to a certain extent. Intravenous administration offers a solution to the systemic distribution of OV drugs but is ambiguous in terms of efficacy and safety. The main reason is the synergistic role of innate and adaptive immunity of the immune system in the response against the HSV-1 oncolytic virus, which is rapidly cleared by the body’s immune system before it reaches the tumor, a process that is accompanied by side effects. This article reviews different administration methods of HSV-1 oncolytic virus in the process of tumor treatment, especially the research progress in intravenous administration. It also discusses immune constraints and solutions of intravenous administration with the intent to provide new insights into HSV-1 delivery for OV therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirusesHerpesvirus 1, HumanOncolytic VirotherapyNeoplasmsHumansAdaptive Immunity

Stichwörter der Autor:innen

HSV-1 oncolytic virus therapycancer immunotherapyherpes simplex virus type 1intravenous injectionmode of administrationoncolytic virus

Autor:innen und Institutionen

  • Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, Qishan Campus, Fujian Normal University, College Town, Fuzhou 350117, China.

ORCID-Profile: Qi Chen

Förderung

  • the Natural Science Foundation of Fujian Province, China
  • Department of Science and Technology of Fujian Province, China

Zitieren

APA

Tang, G., Wang, D., Zhao, X., Feng, Z., Chen, Q., & Shen, Y. (2023). The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043681

Vancouver

Tang G, Wang D, Zhao X, Feng Z, Chen Q, Shen Y. The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043681

BibTeX
@article{Tang2023,
  author = {Tang, Guijin and Wang, Dawei and Zhao, Xiangqian and Feng, Zhihua and Chen, Qi and Shen, Yangkun},
  title = {The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24043681}
}
Kostenlos starten →